. . "To design effective protocols for vaccination and immunotherapy of tumour variants of the same aetiology whose phenotype has been modified by immunoediting, a better understanding of the differences in the mechanisms of specific protective immunity against these tumours are required. For these purposes, experimental murine tumours associated with HPV 16 is available. Aims: (1) Determination of the differences in the mechanisms of protective immunity induced by immunization with tumour cells expressing the same oncoproteins E6/E7, but different in the expression of MHC class I and other immunomodulatory molecules, used as cellular vaccines against variants of tumours with different expression of these molecules. (2) Immunization protocols against model tumours representing variants which escaped from CTL-mediated immune responses will be designed. (3) For these purposes, new lines expressing E6/E7 and distinct in the expression of selected immunomodulatory molecules will be prepared."@en . . . . " immunomodulatory molecules" . . "2010-12-31+01:00"^^ . . . "Mechanismy protektivn\u00ED imunity proti n\u00E1dor\u016Fm li\u0161\u00EDc\u00EDm se v expresi imunomodula\u010Dn\u00EDch molekul" . . "0"^^ . "The crucial role of NK1.1+ cells was found in the induction of protective imunity against MHC I-deficient, HPV16-associated tumours using depletion tests in vivo, cytotoxic tests after prophylatic immunization and specificity of IFNg production."@en . "IAA500520807" . "2013-06-28+02:00"^^ . . "In vivo deple\u010Dn\u00EDmi testy, cytotoxickou aktivitou indukovanou po profylaktick\u00E9 imunizaci a specificitou produkce IFNg byla definov\u00E1na v\u00FDznamn\u00E1 role NK1.1+ bun\u011Bk v indukci protektivn\u00ED imunity proti MHC I-deficientn\u00EDm, HPV16-asociovan\u00FDm n\u00E1dor\u016Fm."@cs . . . "1"^^ . "2008-01-01+01:00"^^ . . "0"^^ . . "5"^^ . "5"^^ . . "2010-03-09+01:00"^^ . "Mechanisms of protective immunity against tumours with different expression of immunodulatory molecules"@en . . . "profylactic immunization; MHC class I antigens; immunomodulatory molecules; tumours associated with human papilloma virus HPV 16"@en . "Pro vypracov\u00E1n\u00ED \u00FA\u010Dinn\u00FDch imuniza\u010Dn\u00EDch a imunoterapeutick\u00FDch strategi\u00ED proti variant\u00E1m n\u00E1dor\u016F stejn\u00E9 etiologie, jejich\u017E fenotyp byl modifikov\u00E1n vlivem imunitn\u00ED odpov\u011Bdi, je nutn\u00E9 l\u00E9pe porozum\u011Bt rozd\u00EDl\u016Fm v mechanismech navozen\u00ED imunity proti t\u011Bmto n\u00E1dor\u016Fm. Pro tyto \u00FA\u010Dely je k dispozici model experiment\u00E1ln\u00EDch my\u0161\u00EDch n\u00E1dor\u016F asociovan\u00FDch s lidsk\u00FDm papilomavirem HPV 16. C\u00EDle: (1) Zji\u0161t\u011Bn\u00ED \u00FA\u010Dinnosti a specificity imunizac\u00ED n\u00E1dorov\u00FDmi bu\u0148kami exprimuj\u00EDc\u00EDmi stejn\u00E9 virov\u00E9 onkoproteiny (E6/E7), ale li\u0161\u00EDc\u00EDmi se v expresi MHC molekul I. t\u0159\u00EDdy a dal\u0161\u00EDch imunomodula\u010Dn\u00EDch molekul, pou\u017Eit\u00FDch jako bun\u011B\u010Dn\u00E9 vakc\u00EDny, proti r\u016Fzn\u00FDm variant\u00E1m n\u00E1dor\u016F, kter\u00E9 se tak\u00E9 li\u0161\u00ED v expresi t\u011Bchto molekul. (2) Navr\u017Een\u00ED imuniza\u010Dn\u00EDch protokol\u016F proti modelov\u00FDm n\u00E1dor\u016Fm reprezentuj\u00EDc\u00EDm varianty, kter\u00E9 unikly imunitn\u00ED odpov\u011Bdi zprost\u0159edkovan\u00E9 cytotoxick\u00FDmi T lymfocyty. (3) P\u0159\u00EDprava nov\u00FDch lini\u00ED li\u0161\u00EDc\u00EDch se v expresi vybran\u00FDch imunomodula\u010Dn\u00EDch molekul a nesouc\u00EDch virov\u00E9 E6/E7 onkoproteiny." . " MHC class I antigens" . . "http://www.isvav.cz/projectDetail.do?rowId=IAA500520807"^^ . "profylactic immunization" .